uk.finance.yahoo.com
JPMorgan Sees Pharma M&A ‘Very Active,’ But ‘Different’ in 2020
Jan.14 -- Christopher Schott, senior pharmaceuticals analyst at JPMorgan, discusses the outlook for M&A deals in the pharmaceutical and biotech industries. He speaks on the sidelines of the JPMorgan Healthcare Conference on "Bloomberg Daybreak: Americas."